Development of Novel Peptide Inhibitors to BAG-1
Applications of Peptidyl-Biomimetics to reduce and eliminate tumor resistance to chemotherapy
978-3-8465-4302-3
3846543020
92
2014-02-26
54.90 €
eng
https://images.our-assets.com/cover/230x230/9783846543023.jpg
https://images.our-assets.com/fullcover/230x230/9783846543023.jpg
https://images.our-assets.com/cover/2000x/9783846543023.jpg
https://images.our-assets.com/fullcover/2000x/9783846543023.jpg
One of the most challenging aspects of treating tumors with chemotherapy is that the tumors can develop a resistance to the chemotherapy and survive while the rest of the healthy, non-cancerous cells perish. Higher doses of chemotherapy deliver fewer positive results and at the expense of greater side effects. The purpose of this book it to identify and exploit a weakness at the molecular level of the anti-apoptotic pathway utilized by cancer cells to turn off the "triggered cell death" mechanism of apoptosis and survive chemotherapy. We specifically target the interaction between the anti-apoptotic protein Bcl-2 Associated Athanogene (BAG-1) and the 70-kilodalton Heat Shock Protein (HSP-70) that is suspected of driving the chemotherapeutic resistance, and seek to disrupt that interaction via peptidyl-biomimetically engineered peptides that are predicted via an in-house computational software named 'Contact" and experimentally verified via Biacore (c) binding assays.
https://morebooks.de/books/cn/published_by/lap-lambert-academic-publishing/47/products
生物化学 ,生物物理学
https://morebooks.de/store/cn/book/development-of-novel-peptide-inhibitors-to-bag-1/isbn/978-3-8465-4302-3